NO913127L - Fremgangsmaate for fremstilling av noeytraliserende hiv-determinanter. - Google Patents

Fremgangsmaate for fremstilling av noeytraliserende hiv-determinanter.

Info

Publication number
NO913127L
NO913127L NO91913127A NO913127A NO913127L NO 913127 L NO913127 L NO 913127L NO 91913127 A NO91913127 A NO 91913127A NO 913127 A NO913127 A NO 913127A NO 913127 L NO913127 L NO 913127L
Authority
NO
Norway
Prior art keywords
procedure
manufacturing
neutralizing hiv
determinants
hiv determinants
Prior art date
Application number
NO91913127A
Other languages
English (en)
Other versions
NO913127D0 (no
Inventor
John A Lewis
Joseph P Davide
Julie Ann Waterbury
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO913127D0 publication Critical patent/NO913127D0/no
Publication of NO913127L publication Critical patent/NO913127L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
NO91913127A 1990-08-13 1991-08-12 Fremgangsmaate for fremstilling av noeytraliserende hiv-determinanter. NO913127L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56665690A 1990-08-13 1990-08-13
US56663890A 1990-08-13 1990-08-13
US56665490A 1990-08-13 1990-08-13

Publications (2)

Publication Number Publication Date
NO913127D0 NO913127D0 (no) 1991-08-12
NO913127L true NO913127L (no) 1992-02-14

Family

ID=27415998

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91913127A NO913127L (no) 1990-08-13 1991-08-12 Fremgangsmaate for fremstilling av noeytraliserende hiv-determinanter.

Country Status (11)

Country Link
EP (1) EP0471407A3 (no)
JP (1) JPH06321808A (no)
KR (1) KR920004422A (no)
AU (1) AU642751B2 (no)
CA (1) CA2048594A1 (no)
FI (1) FI913817A (no)
IE (1) IE912846A1 (no)
IL (1) IL99077A0 (no)
NO (1) NO913127L (no)
NZ (1) NZ239281A (no)
PT (1) PT98633A (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519554A1 (en) * 1991-06-19 1992-12-23 Merck & Co. Inc. Conjugates of the class II protein of the outer membrane of neisseria meningitidis and of HIV-1 related peptides
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
GB2282380A (en) * 1993-09-30 1995-04-05 Merck & Co Inc Conjugate of epitopes of HIV with a protein complex from Neisseria
GB2282378A (en) * 1993-09-30 1995-04-05 Merck & Co Inc Conjugates of epitopes of HIV with a protein complex from Neisseria
CN100478352C (zh) * 1994-07-25 2009-04-15 罗切诊断学有限公司 半抗原标记的肽
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV
DK0787191T4 (da) 1994-10-20 2012-01-30 Pasteur Institut Nukleotidsekvenser af HIV-1 type (eller undertype) O retrovirusantigener
FR2731225B1 (fr) * 1995-03-03 2003-10-31 Pasteur Institut Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique
US7090848B1 (en) * 1998-08-04 2006-08-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
US6911527B1 (en) 1999-01-11 2005-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services HIV related peptides
AU2603100A (en) * 1999-01-11 2000-08-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel hiv related peptides
US8022040B2 (en) * 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
CA1339363C (en) * 1987-05-01 1997-08-26 Alan Ray Flesher Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
NL8702403A (nl) * 1987-10-09 1989-05-01 Stichting Centr Diergeneeskund Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc.
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
WO1990003984A1 (en) * 1988-10-03 1990-04-19 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
IL94558A0 (en) * 1989-06-06 1991-03-10 Merck & Co Inc Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
IL99077A0 (en) 1992-07-15
AU8177791A (en) 1992-02-20
PT98633A (pt) 1992-06-30
JPH06321808A (ja) 1994-11-22
KR920004422A (ko) 1992-03-27
FI913817A (fi) 1992-02-14
NO913127D0 (no) 1991-08-12
EP0471407A3 (en) 1993-05-12
EP0471407A2 (en) 1992-02-19
CA2048594A1 (en) 1992-02-14
IE912846A1 (en) 1992-02-26
NZ239281A (en) 1993-09-27
FI913817A0 (fi) 1991-08-12
AU642751B2 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
NO912848L (no) Substituerte azoler, fremgangsmaate for fremstilling deravog anvendelse av forbindelsene.
NO912051D0 (no) Fremgangsmaate for fremstilling av azolderivater.
NO905285D0 (no) Fremgangsmaate for fremstilling av skumstoffer.
NO883475D0 (no) Fremgangsmaate for fremstilling av antibakterielle kinoloner.
NO912346D0 (no) Fremgangsmaate for fremstilling av aminobenzodiazepiner.
NO912808D0 (no) Framgangsmaate for framstilling av silisium-metall.
NO911122D0 (no) Fremgangsmaate for fremstilling av antihyperkolesterolemiske midler.
NO157805C (no) Fremgangsmaate for fremstilling av et preparat for behandling av urinveisinfeksjoner.
NO912242D0 (no) Sorpsjon av trialkylarsiner.
NO913127L (no) Fremgangsmaate for fremstilling av noeytraliserende hiv-determinanter.
NO911606L (no) Fremgangsmaate for fremstilling av glycidylazidpolymer.
NO912797D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme karbostirilderivater.
NO913360L (no) Fremgangsmaate for fremstilling av syntesegass.
NO913692L (no) Fremgangsmaate for fremstilling av karbapenemforbindelser.
NO905453D0 (no) Fremgangsmaate ved fremstilling av klordioksyd.
NO885200L (no) Fremgangsmaate for fremstilling av pro-legemidler.
NO910556L (no) Fremgangsmaate for fremstilling av 7-amino-3-metoksymetyl-cef-3-em-4-karboksylsyre.
NO901315D0 (no) Fremgangsmaate for fremstilling av modifisert pe40.
TR24863A (tr) ALKALIFOSFAT CÖZELTILERININ üRETILMESINE MAHSUS USUL.
NO903796L (no) Fremgangsmaate for fremstilling av optisk aktive epoksyder.
FI913414A (fi) Foerfarande foer framstaellning av 2-hydroxi-3-halogen-5-nitropyridiner.
NO914563D0 (no) Fremgangsmaate for fremstilling av 3h-puriner
NO902583L (no) Fremgangsmaate for fremstilling av haandloeper for kurvet trapp.
NO875268D0 (no) Fremgangsmaate for fremstilling av urea-formaldehydharpikser.
NO894285D0 (no) Framgangsmaate for framstilling av baatskrog.